Novartis has signed its first antibody-drug conjugate (ADC) collaboration, a licence and development agreement with OBI Pharma to build next-generation ADCs carrying novel payloads. Under the terms, Novartis gains global rights to OBI's patents and conjugation technology for selected undisclosed payload classes, with the option to expand into additional payload categories, while OBI evaluates new coupling approaches for Novartis payloads.
OBI receives a USD 30 million upfront and is eligible for development, regulatory and commercial milestones taking the deal beyond USD 2 billion, plus tiered royalties on net sales.
The transaction signals Novartis's formal move into a modality it had previously advanced mainly through internal programmes, now using external conjugation chemistry to diversify its oncology pipeline without waiting on in-house linker-payload innovation.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation